| pubmed-article:19508175 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19508175 | lifeskim:mentions | umls-concept:C0021743 | lld:lifeskim |
| pubmed-article:19508175 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:19508175 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:19508175 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:19508175 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:19508175 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:19508175 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:19508175 | pubmed:dateCreated | 2009-8-18 | lld:pubmed |
| pubmed-article:19508175 | pubmed:abstractText | Interferon-a (IFN-a) is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-a is limited by the activation of tumour resistance mechanisms. In this regard, we have shown that IFN-a, at growth inhibitory concentrations, enhances the EGF-dependent Ras-->Erk signalling and decreases the adenylate cyclase/cAMP pathway activity in cancer cells; both effects represent escape mechanisms to the growth inhibition and apoptosis induced by IFN-a. The selective targeting of these survival pathways might enhance the antitumor activity of IFN-ain cancer cells, as shown by: i) the combination of selective EGF receptor tyrosine kinase inhibitor (gefitinib) and IFN-a having cooperative anti-tumour effects; ii) the farnesyl-transferase inhibitor R115777 strongly potentiating the anti-tumour activity of IFN-a both in vitro and in vivo through the inhibition of different escape mechanisms that are dependent on isoprenylation of intracellular proteins such as ras; iii) the cAMP reconstituting agent (8-Br-cAMP) enhancing the pro-apoptotic activity of IFN-alpha. IFN-beta is a multifunctional cytokine binding the same receptor of IFN-alpha, but with higher affinity (10-fold) and differential structural interactions. We recently showed that IFN-beta is considerably more potent than IFN-alpha in its anti-tumour effect through the induction of apoptosis and/or cell cycle arrest in S-phase. The emergence of long-acting pegylated forms of IFN-beta makes this agent a promising anti-cancer drug. These observations open a new scenario of anticancer intervention able to strengthen the antitumor activity of IFN-alpha or to use more potent type I IFNs. | lld:pubmed |
| pubmed-article:19508175 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19508175 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19508175 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19508175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19508175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19508175 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19508175 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19508175 | pubmed:issn | 1873-5576 | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:VitaliCC | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:CavagniniFF | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:FacchiniGG | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:AbbruzzeseAA | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:MarraMM | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:HoflandL JLJ | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:CaragliaMM | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:TagliaferroVV | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:ZappavignaSS | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:LambertsS W... | lld:pubmed |
| pubmed-article:19508175 | pubmed:author | pubmed-author:MissoGG | lld:pubmed |
| pubmed-article:19508175 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19508175 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:19508175 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19508175 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19508175 | pubmed:pagination | 690-704 | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:meshHeading | pubmed-meshheading:19508175... | lld:pubmed |
| pubmed-article:19508175 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19508175 | pubmed:articleTitle | Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. | lld:pubmed |
| pubmed-article:19508175 | pubmed:affiliation | Department of Biochemistry and Biophysics, II University of Naples, 80138, Naples, Italy. Michele.Caraglia@unina2.it | lld:pubmed |
| pubmed-article:19508175 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19508175 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:19508175 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19508175 | lld:pubmed |
